CIBC Asset Management Inc Acquires 5,771 Shares of Waters Corporation $WAT

CIBC Asset Management Inc boosted its holdings in Waters Corporation (NYSE:WAT) by 67.1% during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 14,368 shares of the medical instruments supplier’s stock after acquiring an additional 5,771 shares during the quarter. CIBC Asset Management Inc’s holdings in Waters were worth $5,457,000 at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. Mondrian Investment Partners LTD bought a new position in Waters in the 3rd quarter worth about $1,397,000. SG Americas Securities LLC increased its stake in Waters by 543.8% in the 4th quarter. SG Americas Securities LLC now owns 37,244 shares of the medical instruments supplier’s stock worth $14,146,000 after acquiring an additional 31,459 shares during the last quarter. Mackenzie Financial Corp increased its position in shares of Waters by 12.2% during the 3rd quarter. Mackenzie Financial Corp now owns 231,852 shares of the medical instruments supplier’s stock valued at $69,512,000 after purchasing an additional 25,182 shares during the last quarter. Vanguard Group Inc. increased its position in shares of Waters by 3.3% during the 3rd quarter. Vanguard Group Inc. now owns 7,656,891 shares of the medical instruments supplier’s stock valued at $2,295,612,000 after purchasing an additional 246,128 shares during the last quarter. Finally, Alberta Investment Management Corp bought a new position in shares of Waters during the 3rd quarter valued at about $4,677,000. 94.01% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several brokerages have recently commented on WAT. Wolfe Research began coverage on Waters in a research report on Tuesday, June 2nd. They set an “outperform” rating and a $425.00 price objective on the stock. Bank of America increased their price objective on Waters from $370.00 to $400.00 and gave the company a “neutral” rating in a research report on Tuesday, June 2nd. UBS Group increased their price objective on Waters from $330.00 to $375.00 and gave the company a “neutral” rating in a research report on Wednesday, May 6th. TD Cowen increased their price objective on Waters from $345.00 to $385.00 and gave the company a “hold” rating in a research report on Wednesday, May 6th. Finally, Robert W. Baird set a $387.00 price objective on Waters in a research report on Wednesday, May 6th. Three investment analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and eight have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $394.24.

Insiders Place Their Bets

In related news, Director Wei Jiang bought 500 shares of the company’s stock in a transaction that occurred on Monday, March 16th. The stock was bought at an average cost of $289.46 per share, for a total transaction of $144,730.00. Following the acquisition, the director directly owned 3,441 shares of the company’s stock, valued at $996,031.86. The trade was a 17.00% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 0.31% of the stock is owned by corporate insiders.

Waters Trading Down 2.9%

Shares of WAT stock opened at $365.74 on Friday. The stock has a market capitalization of $35.91 billion, a PE ratio of 46.47, a P/E/G ratio of 2.21 and a beta of 1.21. Waters Corporation has a 1-year low of $275.05 and a 1-year high of $414.15. The business has a 50-day moving average of $331.04 and a 200 day moving average of $350.91. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.79 and a quick ratio of 1.13.

Waters (NYSE:WAT) last issued its earnings results on Tuesday, May 5th. The medical instruments supplier reported $2.70 earnings per share for the quarter, beating the consensus estimate of $2.31 by $0.39. The company had revenue of $1.27 billion during the quarter, compared to analysts’ expectations of $1.20 billion. Waters had a return on equity of 15.60% and a net margin of 11.91%.Waters’s quarterly revenue was up 91.4% compared to the same quarter last year. During the same period in the prior year, the business posted $2.25 EPS. Waters has set its Q2 2026 guidance at 2.950-3.050 EPS and its FY 2026 guidance at 14.400-14.600 EPS. As a group, sell-side analysts anticipate that Waters Corporation will post 14.5 earnings per share for the current year.

Waters Company Profile

Waters Corporation is a global provider of analytical instruments, software and services for laboratory and research applications. The company designs, manufactures and sells technologies centered on liquid chromatography, mass spectrometry, separation science, and related sample preparation and detection systems. Its product portfolio includes chromatographs, mass spectrometers, columns and consumables, laboratory informatics and workflow software, as well as technical support and training services that help customers run and interpret complex analyses.

Waters serves a wide range of end markets that include pharmaceutical and biotechnology companies, contract research and testing laboratories, academic and government research institutions, clinical diagnostics, food and environmental testing, and industrial and chemical manufacturers.